2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2189

Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
Abstract Number: 2190

Multi-vendor Multi-site T1ρ and T2 Quantification of Knee Cartilage
Abstract Number: 2191

Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings
Abstract Number: 2192

Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
Abstract Number: 2193

“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial
Abstract Number: 2194

Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers
Abstract Number: 2195

BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Abstract Number: 2196

Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)
Abstract Number: 2197

Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Abstract Number: 2198

Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis
Abstract Number: 2199

Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?
Abstract Number: 2200

Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
Abstract Number: 2201

Developing a Comprehensive Patient-Specific Disease Progression Prediction Model for Knee Osteoarthritis Using Machine/Deep Learning Methods
Abstract Number: 2202

Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014
Abstract Number: 2203

Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].